Glioma, Malignant Clinical Trial
Official title:
Retrospective Analysis of Glioblastoma Patients With Immune Therapies
| NCT number | NCT05356312 |
| Other study ID # | GBM-RWD |
| Secondary ID | |
| Status | Available |
| Phase | |
| First received | |
| Last updated |
The treatment of patients with World Health Organization (WHO) grade 4 malignant glioma has not seen any significant breakthrough the past years. Following surgery and radio / chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. The investigators observed patients with grade IV malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.
| Status | Available |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - malignant glioma, IDH WT Exclusion Criteria: - na |
| Country | Name | City | State |
|---|---|---|---|
| Germany | Zentrum für Humangenetik Tübingen | Tübingen |
| Lead Sponsor | Collaborator |
|---|---|
| Zentrum fur Humangenetik Tuebingen |
Germany,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05557240 -
Neoantigens Phase I Trial in Newly Diagnosed Glioblastoma Patients
|
N/A | |
| Recruiting |
NCT05474573 -
Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases
|
N/A | |
| Recruiting |
NCT05485038 -
General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas
|
N/A | |
| Active, not recruiting |
NCT04547621 -
HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
| Completed |
NCT05806619 -
Glioma: Biomolecular Aspects
|
||
| Not yet recruiting |
NCT04562077 -
Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
|
||
| Recruiting |
NCT06038760 -
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
|
||
| Completed |
NCT04497142 -
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05656053 -
Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
|
||
| Recruiting |
NCT06196918 -
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
|
N/A | |
| Recruiting |
NCT05556486 -
Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem
|
||
| Recruiting |
NCT05406700 -
Niraparib In Recurrent IDH 1/2 Gliomas
|
Early Phase 1 | |
| Recruiting |
NCT05773326 -
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
|
Early Phase 1 | |
| Active, not recruiting |
NCT05063682 -
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
|
Phase 1 | |
| Completed |
NCT05100173 -
Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
|
||
| Completed |
NCT05100602 -
Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
|
||
| Recruiting |
NCT05182905 -
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
|
Early Phase 1 | |
| Recruiting |
NCT06381726 -
Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
|
N/A |